Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Multiple sclerosis

Generic glatiramer acetate — a step toward cheaper MS drugs?

Nature Reviews Neurology volume 12, pages 5–6 (2016)Cite this article

Subjects

A randomized, double-blind, phase III trial of generic glatiramer acetate has shown equivalent efficacy and safety compared with the approved formulation, Copaxone. The impact of approval of generic glatiramer acetate, however, will mainly depend on the pricing of the drug.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lublin, F. D. et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann. Neurol. 73, 327–340 (2013).

    Article  CAS  Google Scholar 

  2. Mikol, D. D. et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 7, 903–914 (2008).

    Article  CAS  Google Scholar 

  3. O'Connor, P. et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing–remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 8, 889–897 (2009).

    Article  CAS  Google Scholar 

  4. Bourdette, D. & Hartung, D. Equivalence of glatiramer acetate generics with branded glatiramer acetate in efficacy and cost for the treatment of multiple sclerosis. JAMA Neurol. http://dx.doi.org/10.1001/jamaneurol.2015.2605 (2015).

  5. Cohen, J. et al. Equivalence of generic glatiramer acetate in multiple sclerosis. A randomized clinical trial. JAMA Neurol. http://dx.doi.org/10.1001/jamaneurol.2015.2154 (2015).

  6. Sormani, M. P. et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann. Neurol. 65, 268–275 (2009).

    Article  Google Scholar 

  7. Johnson, K. P. et al. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45, 1268–1276 (1995).

    Article  CAS  Google Scholar 

  8. Comi, G., Filippi, M. & Wolinsky, J. S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging — measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49, 290–297 (2001).

    Article  CAS  Google Scholar 

  9. Barkhof, F. The clinico-radiological paradox in multiple sclerosis revisited. Curr. Opin. Neurol. 15, 239–245 (2002).

    Article  Google Scholar 

  10. Wolinsky, J. S. et al. GLACIER Study Group. GLACIER: an open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing–remitting multiple sclerosis. Mult. Scler. Relat. Disord. 4, 370–376 (2015).

    Article  Google Scholar 

Download references

Acknowledgements

The author's department has received research support from the Danish Multiple Sclerosis Society, the Danish Medical Research Council, and the European Union Sixth Framework Programme: Life sciences, Genomics and Biotechnology for Health.

Author information

Authors and Affiliations

  1. Department of Neurology, Danish Multiple Sclerosis Center, Rigshospitalet, University of Copenhagen, Copenhagen, 2100, Denmark

    Per Soelberg Sørensen

Authors
  1. Per Soelberg Sørensen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Per Soelberg Sørensen.

Ethics declarations

Competing interests

The author has received personal compensation for serving on scientific advisery boards, steering committees or independent data-monitoring boards for Biogen Idec, Merck Serono, Novartis, Genzyme, Teva Pharmaceutical Industries, GlaxoSmithKline, MedDay Pharmaceuticals and Forward Pharma, and has received speaker honouraria from Biogen Idec, Merck Serono, Teva Pharmaceutical Industries, Genzyme and Novartis. His department has received research support from Biogen Idec, Merck Serono, Teva Pharmaceutical Industries, Baxter, Sanofi Aventis, Novartis, Bayer, RoFAR, Roche and Genzyme.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sørensen, P. Generic glatiramer acetate — a step toward cheaper MS drugs?. Nat Rev Neurol 12, 5–6 (2016). https://doi.org/10.1038/nrneurol.2015.224

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2015.224

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing